UnknownPHASE1, PHASE2NCT05278975
Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma
Studying Pleural mesothelioma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- RS Oncology LLC
- Principal Investigator
- James Spicer, MDGuys Hospital
- Intervention
- RSO-021(drug)
- Enrollment
- 186 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2025
Study locations (10)
- South Mead North Bristol Hopsital, Bristol, United Kingdom
- NHS Greater Glasgow & Clyde, Glasgow, United Kingdom
- Leeds Teaching Hospital, Leeds, United Kingdom
- Facility: HOPE Clinical Trials Facility, Leicester Royal Infirmary, Leicester, United Kingdom
- Barts Health NHS Cancer Institute, London, United Kingdom
- Guys and St Thomas NHS Foundation Trust, London, United Kingdom
- The Royal Marsden, London, United Kingdom
- The Christie NHS, Manchester, United Kingdom
- Northumbria NorthTyne Side General Hospital, North Shields, United Kingdom
- Oxford University Hospitals NHS Foundation, Oxford, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05278975 on ClinicalTrials.govOther trials for Pleural mesothelioma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07192900Fast TILs to Treat Metastatic Cancer Patients With Pleural DiseaseDavid Bartlett, MD
- RECRUITINGNANCT07126509Partial Pleurectomy (Surgery) for Unresectable Pleural MesotheliomaUniversity of Chicago
- RECRUITINGPHASE1, PHASE2NCT07121374NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility StudyUniversity Hospital, Antwerp
- RECRUITINGPHASE1NCT06885697Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including MesotheliomaNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT06840834Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and ChemotherapyIntergroupe Francophone de Cancerologie Thoracique
- RECRUITINGPHASE2NCT06875076Multicenter Single-Arm Study of Ivonescimab (AK112) Combined with Chemotherapy in Pretreated Pleural MesotheliomaThe First Hospital of Jilin University
- RECRUITINGPHASE2NCT06790082The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural MesotheliomaAalborg University Hospital
- RECRUITINGPHASE1NCT06566079Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid TumorsInSilico Medicine Hong Kong Limited